PDF(Pubmed)
Abstract：
The effectiveness of single-fraction 8-Gy radiotherapy for painful bone metastases has been verified in numerous randomized controlled trials. However, few reports have described the effectiveness of single-fraction 8-Gy radiotherapy in painful tumors other than bone metastases. We conducted a retrospective analysis to evaluate the pain response to single-fraction 8-Gy radiotherapy in painful non-bone-metastasis tumors. We included patients who had received single-fraction 8-Gy radiotherapy for such tumors between January 2017 and December 2022, excluding those with brain metastases, hematological tumors and those who received re-irradiation. Pain response assessment was based on the best responses documented in the medical records and conducted by two radiation oncologists. A total of 36 eligible patients were included in this study. The irradiation sites included primary lesions in eight patients, lymph node metastases in eight, muscle metastases in seven, pleural dissemination in four, skin/subcutaneous metastases in four and other sites in five. Pain response was assessed in 24 patients after radiotherapy. Pain response rate was 88% in evaluable patients; 21 of the 24 patients experienced response. The median assessment date for pain response was 37 days (range: 8-156 days) after radiotherapy. Re-irradiation was performed in four patients (11%). Single-fraction 8-Gy radiotherapy seemed to be a promising treatment option for painful non-bone-metastasis tumors and warrants further investigation.
摘要：
在许多随机对照试验中已经证实了单次8-Gy放疗对疼痛性骨转移的有效性。然而,很少有报道描述单级分8-Gy放疗治疗骨转移以外的疼痛性肿瘤的有效性.我们进行了一项回顾性分析，以评估疼痛性非骨转移肿瘤对单次8-Gy放疗的疼痛反应。我们纳入了在2017年1月至2022年12月期间接受过此类肿瘤单次8-Gy放疗的患者，不包括脑转移患者。血液肿瘤和接受再照射的患者。疼痛反应评估基于医疗记录中记录的最佳反应，并由两名放射肿瘤学家进行。共有36名符合条件的患者被纳入本研究。照射部位包括8例患者的原发病灶,八个淋巴结转移，七个肌肉转移，四个胸膜播散，皮肤/皮下转移4个和其他5个部位。对24例患者放疗后的疼痛反应进行了评估。可评估患者的疼痛反应率为88％；24例患者中有21例出现反应。疼痛反应的中位评估日期为放疗后37天（范围：8-156天）。对四名患者（11％）进行了重新照射。单次8Gy放疗似乎是疼痛性非骨转移肿瘤的有希望的治疗选择，值得进一步研究。
